Besides these two genomic markers, also a number of segmental chromosomal aberrations (SCAs), affecting different chromosomes, have been described and it is now assumed that, besides MYCN amplification, the presence of these aberrations does also have a strong effect on the tumor cells, rendering them more aggressive and/or therapy-refractory (12–14). This evidence concerns the gene MYCN and neoplasm.